Abstract:In the past decade, a growing body of evidence has shown that HBsAg quantification (qHBsAg) not only is a useful marker for monitoring natural history of treatment-naïve Chronic HBV Infection (CHB) but can also predict clinical and treatment outcomes [1]. While, other study indicated that, being used alone, qHBsAg is not a suitable marker for evaluating hepatitis activity and distinguishing between cases of HBeAg-negative CHB and inactive HBV carrier state [2]. In our study, we showed that qHBsAg had high predictive value for discrimination of immune tolerance (IT) and Immune Clearance (IC) phase, and it had moderate predictive value for differentiation of low replication (LR) phase and HBeAg Negative Hepatitis (ENH) [3]. While, role of HBeAg quantification (qHBeAg) in natural phases of HBV infection has not been attracted more attention up to now. We found that in HBeAg positive phase of treatment-naïve CHB, qHBsAg and qHBeAg correlated positively (P<0.0001), and both had strong negative correlation with grade of liver inflammation (G) (P<0.0001) and Fibrosis stage (F) (P<0.0001) (unpublished data). Thus, we might speculate that qHBeAg can either be used as a marker of natural phases of HBV infection in HBeAg positive patients. Indeed, we demonstrated that qHBeAg had moderate predictive value for discriminating IT and IC phase [3]. And qHBsAg and qHBeAg had moderate predictive value for F1, F2 and F3 and for G2 and G3 in treatment-naïve HBeAg positive CHB (unpublished data). In recent years, HBcAb quantification (qHBcAb) has been indicated to be associated with HBV infection induced hepatitis [4]. We also suggested that qHBcAb are higher in IC and ENH phases than in IT and LR phases. And qHBcAb correlated positively with grade of liver inflammation. Whereas, the qHBcAb has low divisional value for the intermediate grades of inflammation (unpublished data). Next, we will determine whether qHBcAb is different with liver injury of different etiologies in HBV infection, including HBV infection merged with non-alcoholic fatty liver disease or combined with drug induced liver injury. In all, qHBsAg had high and qHBeAg had moderate predictive value for discrimination of IT and IC phase. And both had moderate predictive value for diagnosis of mild to severe liver fibrosis in treatment-naïve HBeAg positive CHB. Both qHBsAg and qHBcAb had moderate predictive value for differentiation of LR and ENH phase.

Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B

Detection of Hepatitis B Virus Large Surface Protein Using a Time‐Resolved Immunofluorometric Assay

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

The Clinical Significance of Up-Converting Phosphor Immunochromatography in Detecting Hepatitis B Virus Large Envelope Protein in Various Types of Chronic Liver Disease

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

The Combination Detection and Significance of HBV-LP and Serum Hepatitis B Virus Markers in HBV Infected Patients

Characterization and Clinical Application of a Monoclonal Antibody to Hepatitis B Virus Large Surface Proteins

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers

Quantitative Serum HBV Markers in Predicting Phases of Natural History of Chronic HBV Infection.

Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B

Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection

Role of Serum Hepatitis B Virus Marker Quantitation to Differentiate Natural History

Clinical Significance of Detecting Hepatitis B Virus X Antigen and Anti-Hbx Antibody

Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance

4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients

Evaluation on the correlation between HBV-DNA and serum HBV-LP of patients with hepatitis B and its clinical application

Serum Biomarkers of Hepatitis B Virus Infected Liver Inflammation: A Proteomic Study

Examination of Anti-Hbx in Sera from Patients of Chronic Hepatitis B,liver Cirrhosis and Hepatocellular Carcinoma and Its Clinical Significance